IL230510A0 - Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft - Google Patents

Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft

Info

Publication number
IL230510A0
IL230510A0 IL230510A IL23051014A IL230510A0 IL 230510 A0 IL230510 A0 IL 230510A0 IL 230510 A IL230510 A IL 230510A IL 23051014 A IL23051014 A IL 23051014A IL 230510 A0 IL230510 A0 IL 230510A0
Authority
IL
Israel
Prior art keywords
fibrosis
methods
treating diseases
disorders characterized
fibrotic
Prior art date
Application number
IL230510A
Other languages
English (en)
Hebrew (he)
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Publication of IL230510A0 publication Critical patent/IL230510A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL230510A 2011-07-19 2014-01-16 Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft IL230510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509340P 2011-07-19 2011-07-19
US201261662337P 2012-06-20 2012-06-20
PCT/US2012/047468 WO2013013085A2 (en) 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis

Publications (1)

Publication Number Publication Date
IL230510A0 true IL230510A0 (en) 2014-03-31

Family

ID=47558730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230510A IL230510A0 (en) 2011-07-19 2014-01-16 Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft

Country Status (11)

Country Link
US (2) US20140057831A1 (cg-RX-API-DMAC7.html)
EP (1) EP2734220A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014527040A (cg-RX-API-DMAC7.html)
CN (2) CN103890003B (cg-RX-API-DMAC7.html)
AU (1) AU2012283924A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014001268A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842330A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198333A1 (cg-RX-API-DMAC7.html)
IL (1) IL230510A0 (cg-RX-API-DMAC7.html)
RU (1) RU2014105513A (cg-RX-API-DMAC7.html)
WO (1) WO2013013085A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
US20160137714A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
WO2016179106A1 (en) * 2015-05-01 2016-11-10 University Of Miami Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
WO2016197018A1 (en) * 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
JP6933394B2 (ja) * 2018-09-06 2021-09-08 マリン エッセンス バイオサイエンシズ コーポレーション オブ ユーエスエーＭａｒｉｎｅ Ｅｓｓｅｎｃｅ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ ＵＳＡ 組織再生誘導のためのバイオマテリアルデバイスおよび局所用組成物
US11361161B2 (en) * 2018-10-22 2022-06-14 Verint Americas Inc. Automated system and method to prioritize language model and ontology expansion and pruning
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法
CN116768974A (zh) * 2022-03-11 2023-09-19 中山大学 用于预防和/或治疗肾纤维化的多肽化合物
EP4601667A1 (en) 2022-10-10 2025-08-20 Therapeutics by Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201287T5 (es) * 1996-03-22 2007-10-16 Curis, Inc. Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central.
EP1572950B1 (en) * 2002-06-17 2012-10-10 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
WO2006009836A2 (en) * 2004-06-17 2006-01-26 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
HUE026634T2 (en) * 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
SG172970A1 (en) * 2009-01-16 2011-08-29 Agency Science Tech & Res Method of inhibiting proliferation of hepatic stellate cells
WO2010099363A1 (en) * 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Also Published As

Publication number Publication date
US20160058829A1 (en) 2016-03-03
CA2842330A1 (en) 2013-01-24
WO2013013085A2 (en) 2013-01-24
CN106478776A (zh) 2017-03-08
WO2013013085A3 (en) 2014-03-13
JP2014527040A (ja) 2014-10-09
CN103890003B (zh) 2016-08-24
CN103890003A (zh) 2014-06-25
US20140057831A1 (en) 2014-02-27
EP2734220A2 (en) 2014-05-28
AU2012283924A1 (en) 2014-02-06
HK1198333A1 (zh) 2015-04-02
RU2014105513A (ru) 2015-08-27
EP2734220A4 (en) 2015-01-21
BR112014001268A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
IL230510A0 (en) Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
IL231533B (en) Fusion proteins for the treatment of metabolic disorders
EP2677986A4 (en) MOBILE THERAPEUTIC DEVICE AND METHOD THEREFOR
IL229541B (en) Petridine compounds and their uses for the treatment of autoimmune diseases
PL2938740T3 (pl) Chimeryczne peptydy fgf19 do zastosowania w leczeniu zaburzeń gospodarki kwasami żółciowymi
PT2717692T (pt) Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas
IL229226A0 (en) Pirfenidone and anti-fibrotic treatment in selected patients
EP2542266A4 (en) 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
ZA201400562B (en) Axmi205 variant proteins and methods for their use
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
IL231157A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
IL231158A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
EP2773365A4 (en) PEPTIDE ANALOGS FOR THE TREATMENT OF ILLNESSES AND SUFFERING
GB201107396D0 (en) Improvements in methods and apparatus for use in the manufacture of innerspring assemblies
EP2877577A4 (en) ELECTROPORATED AMPHIBIENOO CYTS ISOLATED EXTRACTS AND THEIR USE FOR THE TREATMENT OF ILLNESSES AND DISORDERS
GB201117876D0 (en) Peptides and their use in treatment
IL227818A0 (en) A flexible therapeutic device and a method for using it
HK1196941A (en) The neurotrophic factors manf and cdnf for use in the treatment of retinal disorders